IMDX
Insight Molecular Diagnostics Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-3.26
P/S
22.31
EV/EBITDA
-2.90
DCF Value
$-3.25
FCF Yield
-28.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
4.7%
Operating Margin
-754.1%
Net Margin
-1238.5%
ROE
684.6%
ROA
-195.0%
ROIC
-197.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.1M | $-23.0M | $-0.75 |
| FY 2025 | $4.1M | $-50.2M | $-1.65 |
| Q3 2025 | $260.0K | $-10.9M | $-0.34 |
| Q2 2025 | $518.0K | $-9.7M | $-0.30 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.53
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.